Cfra Upgrades Revvity (NYSE:RVTY) to Buy

Revvity (NYSE:RVTY) was upgraded by stock analysts at Cfra from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Other equities research analysts have also issued research reports about the stock. Evercore reissued an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Royal Bank Of Canada started coverage on shares of Revvity in a report on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price objective on the stock. Bank of America reiterated a “neutral” rating on shares of Revvity in a research report on Wednesday. Weiss Ratings upgraded shares of Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, TD Cowen boosted their target price on shares of Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Six analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $124.43.

Revvity Stock Up 7.9%

Revvity stock opened at $163.55 on Wednesday. The stock has a market capitalization of $18.25 billion, a PE ratio of 77.88, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. Revvity has a 12 month low of $81.22 and a 12 month high of $171.74. The business has a 50 day simple moving average of $145.89 and a 200-day simple moving average of $112.62. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.08. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The business had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. During the same period in the prior year, the company posted $1.18 EPS. The business’s quarterly revenue was up 4.3% on a year-over-year basis. On average, analysts anticipate that Revvity will post 5.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares in the company, valued at approximately $934,738.80. The trade was a 52.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 9,045 shares of company stock valued at $1,281,439. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Revvity

Institutional investors have recently made changes to their positions in the stock. EdgePoint Investment Group Inc. raised its stake in shares of Revvity by 3.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after acquiring an additional 265,204 shares during the period. Jupiter Topco LLC purchased a new position in shares of Revvity during the 2nd quarter worth approximately $961,017,000. Janus Henderson Group PLC boosted its position in shares of Revvity by 2.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock worth $731,386,000 after purchasing an additional 186,956 shares during the period. BlackRock Inc. acquired a new stake in Revvity in the 2nd quarter valued at approximately $852,070,000. Finally, State Street Corp increased its holdings in Revvity by 0.8% in the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after purchasing an additional 32,426 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Key Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported adjusted EPS of $1.38, above analyst estimates of about $1.30, and revenue of $728.9 million versus forecasts of about $694.7 million. Revenue rose 4.3% year over year, while EPS increased from $1.18 a year earlier. Article: Revvity Edges Past Q3 2026 Estimates
• Positive Sentiment: The company raised its 2026 outlook after the quarterly beat. Reports point to Life Sciences growth, margin expansion, AI-related demand and operational execution as contributors to broad-based growth—supporting the case for continued earnings momentum. Article: Q3 Earnings Beat on Life Sciences Strength Article: AI Demand and Operational Execution
• Neutral Sentiment: Revvity reaffirmed its dividend, providing continuity for income-focused shareholders, but the announcement alone does not materially change the growth outlook. Article: Revvity Reaffirms Its Dividend
• Negative Sentiment: Valuation is a key counterweight: one report questions whether the stock is now too expensive. The provided background also shows a high P/E ratio and a share price near its 52-week high, which could leave less room for gains if growth or guidance disappoints. Article: Earnings Beat Might Change the Case for Revvity

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.